BNC Korea Co., Ltd. (KOSDAQ:256840)

South Korea flag South Korea · Delayed Price · Currency is KRW
5,580.00
-280.00 (-4.78%)
At close: Dec 5, 2025
38.46%
Market Cap 381.64B
Revenue (ttm) 98.11B
Net Income (ttm) 13.76B
Shares Out 68.39M
EPS (ttm) 201.77
PE Ratio 27.63
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,940,463
Average Volume 4,605,129
Open 5,830.00
Previous Close 5,860.00
Day's Range 5,530.00 - 5,890.00
52-Week Range 3,475.00 - 6,310.00
Beta 0.76
RSI 53.39
Earnings Date Nov 14, 2025

About BNC Korea

BNC Korea Co., Ltd. engages in the research and development, production, and sale of biomaterials for medicines in South Korea. The company offers BIENOX Inj. for temporary improvement of moderate to severe glabellar wrinkles associated with corrugator muscle and/or procerus muscle activity in adults; Juvegel for temporary improvement of moderate to severe nasolabial folds in adults; and Collapleo Plus, a collagen-based material for the supplementation of damaged or deficient ligaments, tendons, muscles, and fascia. It also provides HA fillers ... [Read more]

Sector Healthcare
Founded 2007
Employees 251
Stock Exchange KOSDAQ
Ticker Symbol 256840
Full Company Profile

Financial Performance

In 2024, BNC Korea's revenue was 89.23 billion, an increase of 10.16% compared to the previous year's 81.00 billion. Earnings were 13.31 billion, a decrease of -48.19%.

Financial Statements

News

There is no news available yet.